Sisram Medical Ltd (HKG: 1696), an Israel-based subsidiary of the Fosun Pharmaceutical Group, has released its unaudited interim financial report for 2024, showing revenues of USD 168.7 million, a slight decrease of 1.7% year-on-year (YOY). The company’s regional revenue breakdown indicates growth in the Asia Pacific, Europe, Middle East, and Africa regions, with revenues of USD 56 million, USD 24 million, and USD 15.4 million, respectively, reflecting increases of 15.5%, 10.0%, and 10.9% YOY. However, North America saw a YOY decline in revenue, reporting USD 67 million, down by 15.7%. The adjusted net profit stood at USD 16.7 million, marking a 19.4% YOY decrease.
Sisram Medical has introduced three new products in the market. Alma Harmony, an anti-aging platform, has been launched in North America, supported by over 130 indication approvals in the US. The Soprano Titanium special edition represents an enhanced version of the Alma flagship hair removal device platform. Additionally, the company has launched Alma IQ, an innovative intelligent skin analysis and consulting solution. Moreover, Sisram’s next-generation hyaluronic acid complex, PROFHILO, has received special clearance for use in Hainan as a unique drug and device product.
Expanding its market reach, Sisram Medical has entered into a licensing agreement with the Canadian firm Prollenium. This deal grants Sisram exclusive distribution rights to Prollenium’s Revanesse injection filling product series across several key markets, including Germany, Austria, Switzerland, Australia, and New Zealand.- Flcube.com
